Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA.

Int J Mol Sci. 2018 Dec 2;19(12). pii: E3837. doi: 10.3390/ijms19123837. Review.

2.

A Spatio-Temporal Model and Inference Tools for Longitudinal Count Data on Multicolor Cell Growth.

Qiao P, Mølck C, Ferrari D, Hollande F.

Int J Biostat. 2018 Jul 7;14(2). pii: /j/ijb.2018.14.issue-2/ijb-2018-0008/ijb-2018-0008.xml. doi: 10.1515/ijb-2018-0008.

PMID:
29981281
3.

Tight Junction Protein Claudin-2 Promotes Self-Renewal of Human Colorectal Cancer Stem-like Cells.

Paquet-Fifield S, Koh SL, Cheng L, Beyit LM, Shembrey C, Mølck C, Behrenbruch C, Papin M, Gironella M, Guelfi S, Nasr R, Grillet F, Prudhomme M, Bourgaux JF, Castells A, Pascussi JM, Heriot AG, Puisieux A, Davis MJ, Pannequin J, Hill AF, Sloan EK, Hollande F.

Cancer Res. 2018 Jun 1;78(11):2925-2938. doi: 10.1158/0008-5472.CAN-17-1869. Epub 2018 Mar 6.

4.

Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process.

Behrenbruch C, Shembrey C, Paquet-Fifield S, Mølck C, Cho HJ, Michael M, Thomson BNJ, Heriot AG, Hollande F.

Clin Exp Metastasis. 2018 Apr;35(4):333-345. doi: 10.1007/s10585-018-9873-2. Epub 2018 Jan 15. Review.

PMID:
29335811
5.

The A2b adenosine receptor antagonist PSB-603 promotes oxidative phosphorylation and ROS production in colorectal cancer cells via adenosine receptor-independent mechanism.

Mølck C, Ryall J, Failla LM, Coates JL, Pascussi JM, Heath JK, Stewart G, Hollande F.

Cancer Lett. 2016 Dec 1;383(1):135-143. doi: 10.1016/j.canlet.2016.09.018. Epub 2016 Sep 28.

PMID:
27693637
6.

Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.

Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, Charafe-Jauffret E, Pham K, Molck C, Rolland N, Bourgaux JF, Prudhomme M, Philippe C, Bravo S, Boyer JC, Canterel-Thouennon L, Taylor GR, Hsu A, Pascussi JM, Hollande F, Pannequin J.

Gut. 2017 Oct;66(10):1802-1810. doi: 10.1136/gutjnl-2016-311447. Epub 2016 Jul 25.

7.

High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.

Xie J, Mølck C, Paquet-Fifield S, Butler L; Australian Prostate Cancer Bioresource, Sloan E, Ventura S, Hollande F.

Oncotarget. 2016 Jul 12;7(28):44492-44504. doi: 10.18632/oncotarget.9876.

8.

mGluR5: exploration of orthosteric and allosteric ligand binding pockets and their applications to drug discovery.

Mølck C, Harpsøe K, Gloriam DE, Mathiesen JM, Nielsen SM, Bräuner-Osborne H.

Neurochem Res. 2014 Oct;39(10):1862-75. doi: 10.1007/s11064-014-1248-8. Epub 2014 Feb 4.

PMID:
24493625
9.

Pharmacological characterization and modeling of the binding sites of novel 1,3-bis(pyridinylethynyl)benzenes as metabotropic glutamate receptor 5-selective negative allosteric modulators.

Mølck C, Harpsøe K, Gloriam DE, Clausen RP, Madsen U, Pedersen LØ, Jimenez HN, Nielsen SM, Mathiesen JM, Bräuner-Osborne H.

Mol Pharmacol. 2012 Nov;82(5):929-37. doi: 10.1124/mol.112.078808. Epub 2012 Aug 16.

PMID:
22899869
10.

Structure-activity relationships for negative allosteric mGluR5 modulators.

Kaae BH, Harpsøe K, Kvist T, Mathiesen JM, Mølck C, Gloriam D, Jimenez HN, Uberti MA, Nielsen SM, Nielsen B, Bräuner-Osborne H, Sauerberg P, Clausen RP, Madsen U.

ChemMedChem. 2012 Mar 5;7(3):440-51. doi: 10.1002/cmdc.201100578. Epub 2012 Jan 20.

PMID:
22267204

Supplemental Content

Support Center